<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101241</url>
  </required_header>
  <id_info>
    <org_study_id>CX-8998-CLN2-001</org_study_id>
    <nct_id>NCT03101241</nct_id>
  </id_info>
  <brief_title>A Phase 2 RCT Study of CX-8998 for Essential Tremor</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cavion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cavion, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a
      screening period of up to 4 weeks (with the exception of subjects on primidone at baseline
      who will be allowed 6 weeks of screening to allow for safe discontinuation). Screening
      results from all patients meeting the eligibility requirements will be further assessed by
      the sponsor medical personnel for final approval of suitability for inclusion in the study.
      Randomized subjects will enter a 4 week double-blind dose-titration treatment period,
      followed by a 1 week safety follow-up period following the last dose of study medication, and
      a scheduled follow-up safety telephone call one week later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a
      screening period of up to 4 weeks (with the exception of subjects on primidone at baseline
      who will be allowed 6 weeks of screening to allow for safe discontinuation). Screening
      results from all patients meeting the eligibility requirements will be further assessed by
      the sponsor medical personnel for final approval of suitability for inclusion in the study.
      Randomized subjects will enter a 4 week double-blind dose-titration treatment period,
      followed by a 1 week safety follow-up period following the last dose of study medication, and
      a scheduled follow-up safety telephone call one week later.

      Subjects will be randomized to one of two treatment groups. Group A will receive titrating
      doses of CX-8998 up to 10 mg BID and Group B will receive placebo. Subject randomization will
      be stratified by presence or absence of a single concomitant anti-tremor medication and by
      site-type (sub-study vs non sub-study).

      Tremor will be assessed via The Essential Tremor Rating Assessment Scale (TETRAS) and
      accelerometry. To reduce the potential for bias in the assessments of efficacy, all subjects
      will be videotaped during the TETRAS performance scale testing according to a consistent
      script. The videotapes will be rated in a blinded manner by qualified, independent raters. A
      subset of subjects will participate in a digital biomarker sub-study.

      Subjects will be screened up to 4 weeks prior to initiation of dosing. Subjects taking
      primidone at screening who are otherwise deemed eligible for participation and are willing to
      discontinue primidone will be allowed an additional 2 weeks of screening (a total of 6 weeks)
      to ensure safe primidone discontinuation. At Baseline, subjects will undergo safety and
      tremor assessments prior to dosing, will receive their first dose of study drug and will be
      monitored for safety for one hour following dosing. For one week subjects will receive 4 mg
      (or matching placebo) twice daily. Subjects will return to the clinic on Day 8 for safety
      monitoring and dose up-titration to 8 mg (or matching placebo) twice daily. At Day 15 (Week
      3) subjects will return to clinic for safety and efficacy assessments and final dose
      up-titration to 10 mg (or matching placebo) twice daily. The final efficacy visit will occur
      at Day 28 (Week 4). A final safety visit will occur at Day 35 (Week 5). Should subjects
      experience intolerable adverse events (AEs) at 4 mg BID, 8 mg BID or 10 mg BID, the dose may
      be decreased at Day 8 or Day 15 to the next lowest dose one time (or 2 mg BID in the case of
      the 4 mg BID dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double-blind, placebo-controlled, parallel-group study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of CX-8998 in reducing essential tremor.</measure>
    <time_frame>4 week period</time_frame>
    <description>Change from Baseline to Day 28 on the TETRAS Performance subscale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>CX-8998</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-8998</intervention_name>
    <description>T-type calcium channel blocker</description>
    <arm_group_label>CX-8998</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent form indicating that the subject has been informed of the
             procedures to be followed, the experimental nature of the therapy, alternatives,
             potential benefits, side effects, risks, and discomforts.

          2. Men or non-pregnant, non-breastfeeding women 18 to 75 years-of-age who are able to
             read and understand English.

          3. Diagnosis of definite or probable essential tremor (ET) as defined by the Tremor
             Investigational Group with involvement of the hands and arms without present causes of
             enhanced physiologic tremor (Deuschl et al.,1998).

          4. Diagnosis of ET before the age of 65.

          5. Tremor severity score of at least 2 in at least one upper extremity on at least one of
             the three maneuvers on the TETRAS scale.

          6. Total TETRAS performance score of at least 15.

          7. One concomitant anti-tremor medication (other than primidone) is allowed. Note:
             Primidone is NOT an allowed anti-tremor medication. If on primidone, subjects are
             allowed to extend their screening period by 2 weeks (for a total of 6 weeks) and
             discontinue primidone under the supervision of the investigator.

          8. Subjects with reproductive capability including all males and women of child-bearing
             potential (WOCBP) must agree to practice continuous abstinence or adequate
             contraception methods (appropriate double barrier method or oral, patch, implant, or
             injectable contraception) from as soon as feasible during screening period until at
             least 30 days after the last dose.

          9. Approval by the sponsor medical personnel as to final suitability for the study.

        Exclusion Criteria:

          1. Exposure to tremorigenic drugs or drug withdrawal states within the 30 days prior to
             the first planned dose of study drug.

          2. Direct or indirect trauma to the nervous system within 3 months preceding the onset of
             tremor

          3. History or clinical evidence of psychogenic tremor origin

          4. Known history of other medical or neurological conditions that may cause or explain
             subject's tremor, including, but not limited to: a. Parkinson's disease b. dystonia c.
             cerebellar disease, other than essential tremor d. Traumatic Brain Injury e. alcohol
             abuse or withdrawal f. mercury poisoning g. hyperthyroidism h. pheochromocytoma i.
             head trauma or cerebrovascular disease within 3 months prior to the onset of essential
             tremor j. multiple sclerosis k. polyneuropathy l. family history of Fragile X syndrome

          5. Prior MR-guided Focused Ultrasound or surgical intervention (e.g., deep brain
             stimulation, ablative thalamotomy or gamma knife thalamotomy).

          6. Botulinum toxin injection in the 6 months prior to screening.

          7. Currently using more than one anti-tremor medication.

          8. Experiencing clinical benefit from and/or is not willing to discontinue primidone

          9. Use of medication(s) in the past month that might produce tremor or interfere with the
             evaluation of tremor, such as, but not limited to: CNS-stimulants, lithium,
             amiodarone, metoclopramide, theophylline, and valproate

         10. Inability to refrain from use of medication/substance(s) that might produce tremor or
             interfere with the evaluation of tremor on study visit days, such as but not limited
             to stimulant decongestants, beta-agonist bronchodilators, caffeine, alcohol and
             tobacco, based on Investigator assessment at baseline.

         11. Positive urine drug screen.

         12. Regular use of more than two units of alcohol per day.

         13. Sporadic use of a benzodiazepine, sleep medication or anxiolytic to improve sleep
             performance. Stable use at a consistent dose is allowed as long as tremor persists
             against the background of regular medication use. Use on the evening prior to a study
             visit is prohibited.

         14. Use of prescription or non-prescription drugs or other products (i.e. grapefruit
             juice) known to be strong inhibitors or inducers of CYP3A4 which cannot be
             discontinued 2 weeks prior to Day 1 of dosing and withheld throughout the study,
             including primidone.

         15. Concurrent illnesses that would be a contraindication to trial participation,
             including, but not limited to: a. Severe arterial thromboembolic events (myocardial
             infarction, unstable angina pectoris, stroke) less than 6 months before screening b.
             NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled
             blood pressure c. Clinically significant ECG d. Known infection with HIV, hepatitis B,
             or hepatitis C, unless curative therapy completed for hepatitis C with negative PCR
             for HCV RNA e. Significant hepatic (AST/ALT &gt; 2X upper limit of normal) or renal
             disease (creatinine clearance &lt;39 mL/min) f. Significant psychiatric history including
             mood disorders and alcohol or substance abuse within the last year g. A current C-SSRS
             score of 4 or 5 at screening or history of suicide attempt at any time during the past
             year h. Clinically significant impaired balance or is considered at increased risk for
             falls i. Symptomatic orthostatic hypotension.

         16. Treatment with an investigational agent within 30 days prior to the first dose of
             CX-8998 or planning to receive an investigational agent during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ryan O'Mara</last_name>
    <phone>1.585.766.2886</phone>
    <email>omara@cavionpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Boyer, PhD</last_name>
    <email>boyer@cavionpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tucson Neuroscience Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CarliAnn Golden</last_name>
      <phone>520-881-8400</phone>
      <email>kjolly@wakeresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Chris Shireman</last_name>
      <email>chris@wnsaz.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rodney Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aeiress Duhart</last_name>
      <phone>501-221-8681</phone>
      <email>aeiress@woodlandintlresearchgrp.com</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Poole</last_name>
      <email>ashley@woodlandintlresearchgrp.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Aukstuolis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Frachiseur</last_name>
      <phone>479-927-3000</phone>
      <email>james@woodlandintlresearchgrp.com</email>
    </contact>
    <contact_backup>
      <last_name>Brittany Smith</last_name>
      <email>brittany@woodlandintlresearchgrp.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fayz Hudefi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lissette Moreno</last_name>
      <phone>858-822-1399</phone>
      <email>L3moreno@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Fatta Nahab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Walton</last_name>
      <phone>619-294-4302</phone>
      <email>awalton@prnsd.com</email>
    </contact>
    <contact_backup>
      <last_name>Deanna Shaffer</last_name>
      <email>dshaffer@prnsd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Thein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart. Isaacson, MD</last_name>
      <phone>561-392-1818</phone>
      <phone_ext>6</phone_ext>
      <email>research@parkinsonscenter.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Isaacson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Fink-Irizarry</last_name>
      <phone>813-974-9915</phone>
      <email>paola@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Shaw</last_name>
      <phone>813-974-1414</phone>
      <email>jshaw@health.usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Theresa Zesiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Kassem</last_name>
      <phone>404-727-3381</phone>
      <email>akassem@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Sommerfeld</last_name>
      <phone>404-712-6997</phone>
      <email>bsommer@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hyder Jinnah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Neurology Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bounphone Chanthavong</last_name>
      <phone>912-790-4837</phone>
      <email>bchanthavong@mcrmed.com</email>
    </contact>
    <contact_backup>
      <last_name>Alistaire Utley</last_name>
      <phone>912-790-4837</phone>
      <email>autley@mcrmed.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gilmore MacGregor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Group</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ZsaZsa Brown</last_name>
      <phone>312-503-4121</phone>
      <email>zsazsa.brown@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Poon</last_name>
      <email>cynthia.poon@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cindy Zadikoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taylor Monken</last_name>
      <phone>913-588-6921</phone>
      <email>tmonken@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>April Langhammer</last_name>
      <email>alanghammer@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rajesh Pahwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Tran</last_name>
      <phone>617-638-7747</phone>
      <email>ctran214@bu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cathi Thomas</last_name>
      <email>neurocat@bu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Okeanis Vaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Stovall</last_name>
      <phone>734-647-4787</phone>
      <email>astovall@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Braden DeWeese</last_name>
      <phone>734-615-5495</phone>
      <email>deweeseb@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kelvin Chou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Ellenbogen, MD</last_name>
      <phone>248-957-8940</phone>
      <email>renee@questri.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital West Bloomfield</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Churchill</last_name>
      <phone>248-661-6270</phone>
      <email>vchurch1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Shagena</last_name>
      <phone>248-325-1358</phone>
      <email>rshagen1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Peter LeWitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacy Pratt</last_name>
      <phone>314-747-5916</phone>
      <email>stacyapratt@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Pecoraro</last_name>
      <phone>314-747-7017</phone>
      <email>mpecoraro@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Criswell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Faggioli</last_name>
      <phone>314-771-6387</phone>
      <email>sfaggioli@slct.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Reno</last_name>
      <email>kreno@slct.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Gruener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darya Tomishon</last_name>
      <phone>212-305-5779</phone>
      <email>dvt2101@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Sheng-Han Kuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael O'Brien</last_name>
      <phone>919-781-2514</phone>
      <email>mobrien@wakeresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Robin Morgan</last_name>
      <phone>919-781-2514</phone>
      <email>rmorgan@wakeresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Singar Jagadeesan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Brown</last_name>
      <phone>937-424-1050</phone>
      <email>jbrown@midwestclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Nita Miller</last_name>
      <email>nmiller@midwestclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Otto Dueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricia McKinney</last_name>
      <phone>615-875-7394</phone>
      <email>tricia.r.mckinney@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendi Welch</last_name>
      <phone>615-936-8102</phone>
      <email>wendi.m.welch@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Hedera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Titi Olubajo</last_name>
      <phone>346-238-9068</phone>
      <email>tolubajo@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Chia Arif</last_name>
      <phone>713-363-8390</phone>
      <email>carif@houstonmethodist.org</email>
    </contact_backup>
    <investigator>
      <last_name>Olga Waln, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential Tremor</keyword>
  <keyword>Movement Disorders</keyword>
  <keyword>thalamocortical dysrhythmias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

